Rurioctocog alfa pegol

Phase 1Small molecule

Sanofi

Rurioctocog alfa pegol is one of 50 small molecule programs targeting Hemophilia A. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophilia aActive, not recruiting

Severe Hemophilia aActive, not recruiting

Hemophilia aPreclinical

Active, not recruiting

Severe Hemophilia aPhase 1

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Phase 3

16 2

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

2 3

Eptacog Alfa

Novo Nordisk

Phase 3

1 4

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

1 5

Valoctocogene Roxaparvovec

BioMarin Pharmaceutical

Phase 3

3 6

Recombinant Factor VIII

Bayer

Phase 3

2 7

Rfviia

Roche

Phase 3

1 8

Marstacimab

Pfizer

Phase 3

1 9

PF-06741086

Pfizer

Phase 3

1 10

Refacto

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Severe Hemophilia a2 trials

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Completed· Bayer logo

Bayer·Phase 1·NCT04015492·18 enrolled

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Completed· Sanofi logo

Sanofi·Phase 1·NCT05042440·13 enrolled

Hemophilia A1 trial

Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®

Completed·SSpanish Society of Thrombosis and Haemostasis··NCT03006965·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Rurioctocog alfa pegol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rurioctocog alfa pegol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rurioctocog alfa pegol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Sanofi

Rurioctocog alfa pegol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Severe Hemophilia a2 trials

Hemophilia A1 trial

References

Drug Info

Quick Facts

Related News